INTRASENSE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.316 EUR | -3.66% |
|
-2.77% | -12.22% |
| 17/04 | Intrasense: an innovative solution for cancer monitoring | CF |
| 09/04 | Guerbet: CE certificate for a platform | CF |
| Sales 2022 | 3.79M 4.05M 338M | Sales 2023 | 3.3M 3.53M 295M | Capitalization | 18.8M 20.1M 1.68B |
|---|---|---|---|---|---|
| Net income 2022 | -3M -3.21M -268M | Net income 2023 | -3M -3.21M -268M | EV / Sales 2022 | 2.85 x |
| Net Debt 2022 | 650K 695K 57.97M | Net cash position 2023 | 3.06M 3.28M 273M | EV / Sales 2023 | 4.76 x |
| P/E ratio 2022 |
-2.97
x | P/E ratio 2023 |
-5.16
x | Employees | 74 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 44.57% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -3.66% | ||
| 1 week | -2.77% | ||
| Current month | +37.39% | ||
| 1 month | +50.48% | ||
| 3 months | -2.47% | ||
| 6 months | -24.94% | ||
| Current year | -12.22% |
1 week
0.30
0.36
1 month
0.210.44
Current year
0.200.44
1 year
0.200.55
3 years
0.201.10
5 years
0.202.43
10 years
0.194.10
| Managers | Title | Age | Since |
|---|---|---|---|
Nicolas Reymond
CEO | Chief Executive Officer | 42 | 12/18/12 |
Julien Coste
DFI | Director of Finance/CFO | - | - |
Frédéric Champ
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michèle Lesieur
CHM | Chairman | 65 | 08/20/08 |
Patrice Rullier
BRD | Director/Board Member | 63 | 15/19/15 |
Nicolas Reymond
CEO | Chief Executive Officer | 42 | 12/18/12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 0.316 | -3.66% | 49,262 |
| 25/24/25 | 0.328 | -1.20% | 45,402 |
| 24/24/24 | 0.332 | +1.84% | 12,525 |
| 23/24/23 | 0.326 | -1.21% | 3,451 |
| 22/24/22 | 0.33 | +1.54% | 11,327 |
Real-time Euronext Paris, April 26, 2024 at 08:24 pm IST
More quotes
Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1,200 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system.
Calendar
11/07/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.22% | 17.61M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +0.65% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- ALINS Stock
